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Expression of human immunodeficiency virus Gag protein and the N-terminal matrix (MA) domain in Escherichia coli
yielded spherical structures in the cytoplasm. When human N-myristoyltransferase was coexpressed, both Gag and MA were
fully myristoylated and spherical structures were relocated in close proximity to the cytoplasmic membrane. However,
neither myristoylated Gag nor MA exhibited tight binding to E. coli membrane, suggesting that myristoylation in E. coli did not
confer membrane affinity on Gag despite the relocation. Our data also suggest that the morphogenetic pathway of Gag
particles in prokaryotic cells differs from that in eukaryotic cells despite biochemical similarities of in the form of Gag
expressed. © 2001 Academic Press
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eINTRODUCTION
Human immunodeficiency virus (HIV) Gag protein, the
major structural component, directs particle assembly.
Expression of Gag protein alone in higher eukaryotic
cells produces Gag virus-like particle (VLP), analogous
to the immature form of the authentic HIV particle (Ghey-
sen et al., 1989; Hoshikawa et al., 1991; Smith et al.,
1993). A number of genetic studies have elucidated the
minimal regions essential for VLP production and have
suggested that a dominant assembly region lies in the
capsid (CA) domain, the central region of Gag protein
(Borsetti et al., 1998; Dorfman et al., 1994; Reicin et al.,
1995). In contrast, the C-terminal p6 domain is largely
dispensable (Gheysen et al., 1989; Hoshikawa et al.,
1991; Jowett et al., 1992). Interestingly, in simian immu-
nodeficiency virus, the N-terminal matrix (MA) domain
alone is capable of VLP production (Giddings et al., 1998;
Gonzalez et al., 1993). Although HIV MA was reported
initially to be insufficient for VLP formation (Giddings et
al., 1998), more recent evidence has shown that the MA
domain is capable of release of VLP (Wang et al., 1999).
When Gag protein is synthesized in the cytosol, Gag is
extensively myristoylated at the N-terminal glycine resi-
due and then targeted to the plasma membrane, where
assembly occurs. The obligatory role of N-myristoylation
in Gag targeting and binding to the plasma membrane
has been demonstrated by a number of studies in which
nonmyristoylated Gag protein, obtained by site-directed
1 To whom correspondence and reprint requests should be ad-
ressed. Fax: 181-3-5791-6120. E-mail: ymorikawa@kitasato.or.jp.343mutagenesis, fails to target to the plasma membrane and
results in no virus particle production (Bryant and Ratner,
1990; Gheysen et al., 1989; Gottlinger et al., 1989). In
ontrast, N-myristoylation of only MA is insufficient to
onfer membrane affinity (Hermida-Matsumoto and
esh, 1999; Paillart and Gottlinger, 1999; Spearman et al.,
997; Zhou and Resh, 1996). N-myristoylation refers to
ovalent linkage of a myristoyl moiety to the N-terminal
lycine of a protein, a modification that occurs cotrans-
ationally (Wilcox et al., 1987). This process consists of
wo sequential reactions: activation of myristic acid to
yristoyl-CoA by acyl-CoA synthetase and transfer of the
yristoyl moiety to the N-terminal glycine residue by
-myristoyltransferase (NMT). Both enzymes have been
solated from eukaryotic cells, including yeast cells, and
howed full activity when used in in vitro assays (Abe et
l., 1992; Boutin et al., 1993; Knoll et al., 1994; Towler et
l., 1987). In contrast, bacteria cells are deficient in NMT
Duronio et al., 1990) but not in the former enzyme (Black
t al., 1992; Kameda et al., 1985), so that Gag protein
expressed in Escherichia coli remains nonmyristoylated
and forms spherical structures inside cells (Gross et al.,
1998), ostensibly similar to VLP in the perinuclear area of
eukaryotic cells expressing nonmyristoylated Gag pro-
tein (Chazal et al., 1994; Morikawa et al., 1996). It has
been reported that various protein substrates including
HIV Gag were myristoylated in E. coli concomitant with
coexpression with yeast NMT (Bryant et al., 1991; Duro-
nio et al., 1990, 1991). An assumption from this work,
based on previous findings with HIV Gag, was that my-
ristoylation of Gag protein in E. coli cells would allow
Gag targeting to the cytoplasmic membrane. If, however,
0042-6822/01 $35.00
Copyright © 2001 by Academic Press
All rights of reproduction in any form reserved.
w
p
g
g
p
c
344 MORIKAWA ET AL.eukaryote-specific cellular elements such as the cy-
toskeleton are involved in Gag transport (Liu et al., 1999;
Rey et al., 1996), then myristoylation of Gag in E. coli may
be insufficient in itself to drive membrane binding. To
address these questions, we constructed a dual expres-
sion system of human NMT (hNMT) and HIV Gag pro-
teins in E. coli and subsequently carried out electron
microscopic analysis of the expressed products.
RESULTS AND DISCUSSION
Coexpression of hNMT and Gags in E. coli
The pairs of plasmids used for dual expression of
HIV-1 Gags and hNMT are illustrated in Fig. 1. The cDNA
encoding hNMT was cloned from a cDNA library of HeLa
cells (Stratagene). As an N-terminal extension of six
histidine residues has been shown not to affect hNMT
FIG. 1. Schematic representation of plasmid constructs used for dual
expression of HIV Gag and hNMT in E. coli. The cDNA encoding hNMT
as cloned in-frame with the polyhistidine-encoding sequence of the
TrcHisA vector (Invitrogen), which contains an ampicillin resistance
ene (AmpR) and ColE1 origin. The HIV-1 (IIIB strain) gag gene encod-
ing the Gag region but lacking the C-terminal p6 domain and the gag
ene encoding the MA domain were cloned downstream of the tac
romoter of pALTER-Ex2 vector (Promega), which contains a tetracy-
line resistance gene (TetR) and p15A origin.
FIG. 2. Expression of Gag and hNMT proteins in E. coli. E. coli cells
and the pTrcHisA vector containing the gag genes. After IPTG inductio
blotting using anti-HIV-1 CA (A) or anti-MA (B) monoclonal antibody an
Lanes: M, low-molecular-weight markers (Bio-Rad); 0, before inductio
cotransformed with the hNMT cDNA-containing and the gag gene (lacki
cDNA-containing and the MA cDNA-containing vectors.enzymatic activity by an in vitro assay (McIlhinney et al.,
1994), hNMT was placed in-frame with the polyhistidine-
encoding sequence of pTrcHisA (Invitrogen) and this
construct expressed a 53- to 54-kDa hNMT protein with
the addition of six histidine residues at the N-terminus.
Full-length HIV-1 Gag protein is also 55 kDa, and to
distinguish Gag protein from coexpressed hNMT by mo-
lecular weight, a C-terminal p6 domain deletion of Gag
was carried out. The p6 domain has been shown not to
be required for either membrane association (Ono et al.,
2000) or assembly (Gheysen et al., 1989; Hoshikawa et
al., 1991; Jowett et al., 1992). The deleted gag gene was
cloned into a pALTER-Ex2 plasmid (Promega). In parallel,
the N-terminal MA domain of Gag was cloned into pAL-
TER-Ex2. E. coli cells were cotransformed with pairs of
the hNMT-containing and the HIV-1 gag gene-containing
vectors. Expression of both proteins was carried out by
addition of isopropyl b-D-thiogalactopyranoside (IPTG)
and monitored by Western blotting using anti-polyhisti-
dine monoclonal antibody (Sigma) for polyhistidine-
tagged hNMT or anti-HIV-1 CA or MA monoclonal anti-
body. As shown in Fig. 2, a low level of hNMT expression
was detected before IPTG induction, although the yield
increased after induction, suggesting that expression of
hNMT from the trc promoter was leaky (Fig. 2C). In
contrast, expression of Gag proteins from the tac pro-
moter was tightly regulated by IPTG addition (Figs. 2A
and 2B). Thus, in our dual expression system, hNMT was
present before the induction of Gag proteins.
Reconstitution of Gag myristoylation in E. coli
To examine whether Gag protein was myristoylated in
E. coli cells by coexpression of hNMT, cells cotrans-
formed with the pair-wise combinations of vectors were
otransformed with the pALTER-Ex2 vector containing the hNMT cDNA
oli cells were lysed and subjected to SDS–PAGE followed by Western
polyhistidine monoclonal antibody (C) for polyhistidine-tagged hNMT.
, and 4, 1, 2, and 4, h after induction, respectively. (A and C) E. coli
p6 domain)-containing vectors. (B) E. coli cotransformed with the hNMTwere c
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345RELOCATION OF HIV Gag PARTICLES MYRISTOYLATED IN E. colimetabolically labeled with [9,10(n)-3H]myristic acid fol-
owing IPTG induction and subjected to SDS–PAGE and
luorography (Fig. 3A). When only hNMT was expressed,
53- to 54-kDa protein was labeled with [3H]myristic
acid, suggesting that hNMT itself was myristoylated (Fig.
3A, lane 1), as reported for yeast NMT (Duronio et al.,
1990). When the Gag protein lacking the p6 domain or
the MA domain was coexpressed with hNMT, additional
labeling of a 50-kDa or a 17-kDa protein, equivalent to
Gag or MA, was detected, indicating myristoylation of
Gag proteins in E. coli (Fig. 3A, lanes 2 and 3). The
myristoylation of Gag was completely dependent on the
presence of hNMT (Fig. 3A, lanes 4 and 5).
The myristoylation efficiency of Gag in this system was
estimated by a dual labeling with [35S]methionine (for the
level of protein synthesis) and with [9,10(n)-3H]myristic
cid (for the level of myristoylation). Following culture in
9 medium supplemented with 19 amino acids without
ethionine, E. coli cells were metabolically labeled with
35
FIG. 3. Myristoylation of Gag protein synthesized in E. coli. (A)
Detection of myristoylated proteins in E. coli. E. coli cells, cotrans-
formed with pairs of the pALTER-Ex2 vector and the pTrcHisA vector,
were metabolically labeled with [9,10(n)-3H]myristic acid following IPTG
nduction and subjected to SDS–PAGE and fluorography. Lanes: M,
14C-rainbow protein molecular weight markers (Amersham Pharmacia
iotech); 1, E. coli cells cotransformed with the pTrcHisA vector con-
aining the hNMT cDNA and the parental pALTER-Ex2 vector; 2, E. coli
ith the hNMT cDNA-containing pTrcHisA vector and the gag gene
(lacking the p6 domain)-containing pALTER-Ex2 vector; 3, E. coli with
the hNMT cDNA-containing pTrcHisA vector and the MA cDNA-con-
taining pALTER-Ex2 vector; 4, E. coli with the parental pTrcHisA vector
and the gag gene (lacking only the p6 domain)-containing pALTER-Ex2
vector; 5, E. coli with the parental pTrcHisA vector and the MA cDNA-
ontaining pALTER-Ex2 vector. (B) Synthesis and myristoylation of Gag
n E. coli. E. coli cells, cotransformed with the pALTER-Ex2 vector
ontaining the hNMT cDNA and the pTrcHisA vector containing the gag
ene (lacking the p6 domain), were cultured in M9 medium supple-
ented with 19 amino acids (excluding methionine) and metabolically
abeled with [35S]methionine (88,900 dpm/pmole) or with [9,10(n)-
3H]myristic acid (50,700 dpm/pmole) for 5 min soon after IPTG induc-
tion. After sonication, the cell lysate was subjected to immunoprecipi-
tation with anti-CA monoclonal antibody and the immunocomplexes
were analyzed by SDS–PAGE followed by fluorography. For quantita-
tion, the radiolabeled bands were excised and measured by a liquid
scintillation counter. Lanes: M, 14C-rainbow protein molecular weight
markers (Amersham Pharmacia Biotech); 1, 35S-labeled; 2, 3H-labeled.S]methionine (88,900 dpm/pmole) or with [9,10(n)-3H]myristic acid (50,700 dpm/pmole). Immunoprecipita-
ion with anti-CA antibody and subsequent SDS–PAGE
evealed that both [35S]methionine and [3H]myristic acid
ere incorporated into the 50 kDa of the Gag protein
acking the p6 domain (Fig. 3B). When the radiolabeled
ands were excised and measured by a liquid scintilla-
ion counter, 58,218 dpm of 35S (the mean count obtained
rom triplicate experiments) corresponding to 0.655
mole of methionine and 1,980 dpm of 3H (the mean
ount obtained from triplicate experiments) correspond-
ng to 0.0391 pmole of myristol moiety were found to be
ncorporated. When adjusted for the number of methio-
ine sites on this Gag construct (16 in the Gag protein
acking the p6 domain), the efficiency of 3H incorporation
as calculated to be ;95% of the total Gag molecules.
his result suggests that HIV Gag was fully myristoylated
n E. coli by coexpression with hNMT. A similar level of
3H incorporation was observed for MA, although as no
35S label was detected due to a lack of methionine sites
except for the initial methionine codon), a formal mea-
ure of efficiency cannot be made.
ellular localization and membrane affinity of
yristoylated Gag protein
To explore the possibility that myristoylated Gag pro-
eins were targeted to the cytoplasmic membrane of E.
oli, electron microscopy of expressing cells was per-
ormed. When the Gag protein lacking the p6 domain
lone was expressed, spherical structures with a diam-
ter of 30–70 nm were observed in E. coli cells (Fig. 4A),
onfirming recent reports in which retroviral Gag pro-
eins (e.g., Mason-Pfizer monkey virus, Rous sarcoma
irus, and HIV) assemble into spherical particles inside
. coli cells (Campbell and Vogt, 1997; Gross et al., 1998;
likova et al., 1995). When coexpressed with hNMT,
pherical structures were also present but were found
xclusively in close proximity to the cytoplasmic mem-
rane of the E. coli cells (Figs. 4B and 4C). Expression of
he MA domain in E. coli cells exhibited similar morphol-
ogy and relocation. Spherical structures with a diameter
of 30–80 nm were observed inside the E. coli cells
expressing the MA domain alone (Fig. 4D), consistent
with previous reports that MA alone produces spherical
VLP (Wang et al., 1999). When coexpressed with hNMT,
spherical structures were found mainly in close proximity
to the cytoplasmic membrane (Figs. 4E and 4F). No
spherical structures were observed in the E. coli cells
expressing hNMT alone. These findings were confirmed
when the numbers of spherical structures in close prox-
imity to the cytoplasmic membrane were counted for the
E. coli cells expressing and lacking hNMT (Table 1). The
morphogenetic features of myristoylated Gag expression
in E. coli differs both from that described in higher eu-
karyotic cells in which electron-dense patches of Gag
were observed on the extruded plasma membrane pro-
e
t
a
346 MORIKAWA ET AL.FIG. 4. Electron microscopic examination of E. coli cells. Following IPTG induction, E. coli cells were incubated at 37°C for 3 h in culture broth
supplemented with 10 mM myristic acid. The cells were fixed with 2% glutaraldehyde and 1% osmium tetroxide and subjected to ultrathin section
lectron microscopic analysis. All micrographs are at the same magnification; scale bar, 100 nm. (A) E. coli expressed with the Gag protein lacking
he p6 domain alone; (B and C) E. coli coexpressed with hNMT and the Gag protein lacking the p6 domain; (D) E. coli expressed with the MA domain
lone; (E and F) E. coli coexpressed with hNMT and the MA domain.
347RELOCATION OF HIV Gag PARTICLES MYRISTOYLATED IN E. coliFIG. 4—Continued
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348 MORIKAWA ET AL.ducing a nascent particle (Gelderblom et al., 1989; Ner-
mut et al., 1994) and from that in yeast cells in which Gag
was targeted to the plasma membrane but yielded an
electron-dense layer on the plasma membrane and no
VLP structures (Jacobs et al., 1989). It is likely that myr-
istoylated Gag protein in E. coli does not target to the
cytoplasmic membrane before assembly but rather at-
taches to the membrane after assembly, similar to the
preassembly observed for type B and D retrovirus Gag
proteins (Gelderblom et al., 1989; Krausslich and Welker,
1996). Thus, despite efficient myristoylation by coexpres-
sion of hNMT in E. coli, the morphogenetic features of
Gag following expression were not as observed in eu-
karyotic cells.
TABLE 1
Expression in
E. coli cells
Number of
cells counted
Number of spherical structures
Membrane proximal Cytoplasmic
ag 23 18 68
ag 1 hNMT 23 60 12
MA 25 20 76
MA 1 hNMT 25 56 24
Note. A membrane-proximal particle was defined as a spherical
structure that was present within a distance of 30 nm from the cyto-
plasmic membrane. The number of “cytoplasmic” particles shows the
total number of particles observed in E. coli cells minus the number of
membrane-proximal particles.
FIG. 5. Equilibrium flotation centrifugation of E. coli membrane. Ex
Following formation of E. coli spheroplasts and subsequent sonicatio
equilibrium flotation centrifugation using a 70–60–10% (w/v) sucrose s
collected from the bottom to the top (left to right) and subjected to SDS–P
antibody. (A) E. coli cells expressing the Gag protein lacking the p6 dolone (upper); coexpressed with hNMT (lower). Lane M shows low-moleculaTo investigate whether the structures observed in
close proximity to the cytoplasmic membrane are asso-
ciated with the membrane, membrane flotation experi-
ments were carried out. E. coli spheroplasts were pre-
pared by the lysozyme–EDTA method (Birdsell and Cota-
Robles, 1967) and, following sonication, the membrane
fractions were separated by equilibrium flotation centrif-
ugation in sucrose step gradients. The Gag antigen in
the gradient fractions was detected by Western blotting
using either anti-CA or anti-MA antibody. As expected,
when E. coli expressing the Gag protein lacking the p6
domain alone was analyzed, all Gag molecules were
found in the bottom fractions where membrane-unbound
Gags sedimented (Fig. 5A, upper). When Gag coex-
pressed with hNMT was analyzed similarly, a small frac-
tion of Gag antigen was found at the interface between
10 and 60% sucrose at the buoyancy of membrane-bound
materials, but the majority of Gag was detected in the
membrane-unbound fractions (Fig. 5A, lower). Similar
flotation profiles were observed for MA. Expression of
MA alone and coexpression of MA and hNMT showed
that MA molecules were wholly detected in the mem-
brane-unbound fractions, although in the latter case, a
mere trace of MA antigen was found in the membrane-
bound fractions (Fig. 5B). These results suggest that
myristoylation of HIV Gag in E. coli did not confer tight
attachment to the membrane bilayer despite the reloca-
tion to within close proximity to the membrane.
n of proteins was carried out as described in the legend for Fig. 4.
ell lysate was clarified by low-speed centrifugation and subjected to
dient. After equilibrium centrifugation, fractions of the gradient were
llowed by Western blotting using anti-CA (A) or anti-MA (B) monoclonal
B) E. coli cells expressing the MA domain. Expressed with Gag or MApressio
n, the c
tep gra
AGE fo
main. (
r-weight markers (Bio-Rad).
349RELOCATION OF HIV Gag PARTICLES MYRISTOYLATED IN E. coliAlthough all the data described above suggest that
the biochemical and biological behaviors were similar
between Gag and MA, treatment with Triton X-100
revealed significant differences. The Gag lacking the
p6 domain and the MA materials was recovered from
the 70–60% interface of the sucrose step gradients
and treated with 0.5% Triton X-100. When the deter-
gent-treated Gag materials were recentrifuged on 20–
70% linear sucrose gradients, the majority of Gag
molecules were found near the bottom of the tubes
where the untreated Gag materials sedimented, sug-
gesting that the Gag complex was not disrupted in
nonionic detergents (Fig. 6A). In contrast, when the
MA materials were similarly analyzed on linear su-
crose gradients, the detergent-treated MA molecules
occurred in the least dense fractions, while the un-
treated MA materials were sedimented near the bot-
tom of the tubes, suggesting that the MA complex was
sensitive to detergent (Fig. 6B). Similar findings were
observed when myristoylated Gag/MA materials were
analyzed following treatment with Triton X-100 (data
not shown). These results were consistent with previ-
ous reports that a MA complex is dissociated by de-
tergent treatment but a complex of Gag precursors is
stable (Morikawa et al., 2000; Stewart et al., 1990;
Wang et al., 1999), although aggregation with cellular
components cannot be ruled out in our Gag/MA com-
plex preparations.
In summary, despite the correct protein modifica-
FIG. 6. Gradient analysis of Gag and MA expressed in E. coli cells
materials were recovered from the 70–60% interface of the sucrose step
The materials were centrifuged on 20–70% (w/v) sucrose linear gradie
to right) were analyzed by SDS–PAGE followed by Western blotting usin
domain. (B) The MA proteins. Untreated (upper); treated with detergentions and the bioactivity shown by efficient assembly,Gag antigen expressed in E. coli did not exhibit the
same morphogenetic features as those that it ex-
pressed in eukaryotic cells. We suggest two possible
explanations for these observations, although other
possibilities cannot be ruled out, as bacteria cells are
totally different from eukaryotic cells. First, the data
may indicate that Gag targeting in eukaryotic cells is
not due to free diffusion to the plasma membrane but
may involve another cellular element(s) such as a
cytoskeleton network. Some cytoskeletal elements
(e.g., actin) have been reported to be copurified with
Gag protein (Liu et al., 1999; Rey et al., 1996) through
a tight binding to the nucleocapsid domain of Gag
(Wilk et al., 1999), although other studies have failed to
show a convincing association (Perrin-Tricaud et al.,
1999). Second, a nonprotein component(s) of eukary-
otic cells may be essential for authentic Gag morpho-
genesis. Recent chemical analysis has shown that
virus particles such as influenza and HIV contain a
lipid composition different from that of the host plasma
membrane, suggesting that budded viruses selectively
incorporate lipid microdomains or rafts (Aloia et al.,
1993; Scheiffele et al., 1999) that are enriched in sphin-
golipid and cholesterol (Simons and Ikonen, 1997).
Myristoylation and palmitoylation are commonly used
signals for raft targeting and increase the affinity of
proteins for such rafts (Melkonian et al., 1999). The
lack of tight membrane association of myristoylated
ing detergent treatment. The Gag lacking the p6 domain and the MA
nts described in the legend for Fig. 5 and treated with 0.5% Triton X-100.
°C and 120,000g overnight. Fractions from the bottom to the top (left
CA (A) or anti-MA (B) monoclonal antibody. (A) The Gag lacking the p6
r). Lane M shows low-molecular-weight markers (Bio-Rad).follow
gradie
nts at 4
g anti-
t (loweHIV Gag observed here may be explained by the
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350 MORIKAWA ET AL.absence of sphingolipid cholesterol in E. coli mem-
brane.
MATERIALS AND METHODS
Construction and coexpression of hNMT and HIV-1
gag genes
The cDNA encoding hNMT was isolated from a cDNA
library of HeLa cells (Stratagene) by PCR using a forward
primer, 59-CGCGGCTAGCATGAACTCTTTGCCAGCAGAG-
AG-39, and a reverse primer, 59-CGCGGAATTCTTATTGTAG-
CACCAGTCCAACCT-39. Dideoxynucleotide sequencing re-
vealed that the cDNA contained two silent mutations com-
pared with previous reports of hNMT derived from HepG2
cells (Duronio et al., 1992). The PCR fragment was placed
in-frame with the six-histidine-encoding sequence of a
pTrcHisA plasmid (Invitrogen). The HIV-1 (IIIB strain) gag
genes encoding the MA domain and the Gag protein but
lacking the C-terminal p6 domain were amplified by PCR
using a forward primer, 59-CGCGGGATCCATGGGTGC-
GAGAGCGTCAGT-39, and reverse primers 59-CGCGGAAT-
TCAGTAATTTTGGCTGACCTGACTG-39 (for the MA domain)
and 59-CGCGGAATTCTCAATTAGCCTGTCTCTCAG-39 (for
the Gag protein lacking the C-terminal p6 domain). The PCR
fragments were cloned downstream of the tac promoter
present in a pALTER-Ex2 plasmid (Promega).
E. coli cells were cotransformed with pairs of the
hNMT-containing and the HIV-1 gag gene-containing
vectors and grown at 37°C in 2xYT broth with ampicillin
and tetracycline to maintain selection for both plasmids.
Expression of both proteins was carried out by addition
of IPTG.
Western blotting
Expression of proteins in E. coli cells was monitored
by Western blotting using anti-polyhistidine monoclonal
antibody (Sigma) for polyhistidine-tagged hNMT or anti-
HIV-1 CA or MA monoclonal antibody (Medical Research
Council AIDS Reagent Repository, National Institute for
Biological Standards and Control, Herz, UK) and anti-
mouse IgG alkaline phosphatase conjugate (Cappel).
Metabolic labeling and immunoprecipitation
E. coli cells were metabolically labeled with 500 mCi of
[9,10(n)-3H]myristic acid at 37°C for 30 min following
PTG induction and subjected to SDS–PAGE. To estimate
he myristoylation efficiency, E. coli cells were cultured in
9 medium supplemented with 19 amino acids (each 10
mg/ml, excluding methionine) for 3 h and metabolically
labeled with [35S]methionine (Amersham Pharmacia Bio-
tech; 88,900 dpm/pmole adjusted by dilution with cold
methionine) or with [9,10(n)-3H]myristic acid (Amersham
harmacia Biotech; 50,700 dpm/pmole adjusted by dilu-
ion with cold myristic acid) at 37°C for 5 min soon after
PTG addition. After sonication, the cells were lysed inIPA buffer and subjected to immunoprecipitation with
nti-CA monoclonal antibody. The immunocomplexes
ere analyzed by SDS–PAGE. For quantitation, the radio-
abeled bands were excised and measured by a liquid
cintillation counter. Fluorography was carried out using
mplify (Amersham Pharmacia Biotech).
quilibrium flotation centrifugation and subsequent
etergent treatment
Equilibrium flotation centrifugation with membrane
as described previously (Ono and Freed, 1999; Paillart
nd Gottlinger, 1999) and utilized in our experiments with
inor modifications. For preparation of E. coli sphero-
lasts, lysozyme and EDTA were added to final concen-
rations of 20 mg/ml and 1 mM, respectively, and cells
ere incubated at room temperature for 10 min. Follow-
ng a washing, spheroplasts were disrupted by brief
onication and the cell lysates were clarified at 4°C and
000 rpm for 10 min. The supernatants were adjusted to
0% (w/v) sucrose, layered at the bottom of 70–60–10%
w/v) sucrose step gradients in phosphate-buffered sa-
ine, and subjected to equilibrium flotation centrifugation.
entrifugation was performed in an SW55 rotor (Beck-
an) at 4°C at 120,000g overnight. Fractions of the gra-
ients were collected from the bottom to the top and
ubjected to SDS–PAGE followed by Western blotting.
In some experiments, Gag and MA were recovered
rom the 70–60% interface of the sucrose step gradients.
ollowing treatment with 0.5% Triton X-100 for 10 min, the
aterials were layered on 20–70% (w/v) sucrose linear
radients in phosphate-buffered saline and centrifuged
t 4°C and 120,000g overnight.
lectron microscopy
The procedure for microscopic examination was de-
cribed previously (Goto et al., 1990). Briefly, E. coli cells
ere collected and fixed with 2% glutaraldehyde in 50
M cacodylate buffer (pH 7.2) at 4°C for 2 h prior to
reatment with 1% osmium tetroxide in 50 mM cacodylate
uffer (pH 7.2) at 4°C for 1 h. Ultrathin sections were
tained with uranyl acetate and lead citrate and exam-
ned with an electron microscope (Hitachi H-800).
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